Investigating the Optimal Management of Dolutegravir Resistance

This study is investigating the best way to manage HIV in people whose virus has become resistant to a common HIV drug called dolutegravir (DTG). It aims to find the most effective treatment switch strategy. **You may be eligible if...** - You are 1 year of age or older (with guardian consent for minors) - You have confirmed HIV-1 infection - You have been on a dolutegravir-containing treatment regimen for at least 6 months - Your most recent HIV viral load is 1,000 copies/mL or higher (meaning your current treatment is not controlling the virus) **You may NOT be eligible if...** - You previously switched HIV treatment because of confirmed or suspected treatment failure on a protease inhibitor or integrase inhibitor regimen - You are currently taking an NNRTI or PI-based regimen alongside dolutegravir - You are unlikely to complete follow-up (e.g., planning to relocate away from the study site) Talk to your doctor to see if this trial is right for you.